160 phenotypes from 10 alleles in 17 genetic backgrounds

Allelic Composition Genetic Background	Annotated Term	Reference
Bmal1em1Bwu/Bmal1em1Bwu C57BL/6-Bmal1em1Bwu	abnormal intestine physiology	J:340220
	abnormal macrophage physiology	J:340220
Bmal1tm1.1Ljm/Bmal1tm1.1Ljm Tg(Mylk-cre)1Ljm/0 involves: C57BL/6	abnormal parturition	J:188253
	delayed parturition	J:188253
	early parturition	J:188253
	normal homeostasis/metabolism phenotype	J:188253
Bmal1tm1.1Ljm/Bmal1tm1.1Ljm Tmem163Tg(ACTB-cre)2Mrt/0 involves: C57BL/6 * FVB/N	abnormal circadian behavior	J:188253
	decreased locomotor activity	J:188253
Bmal1tm1.1Shbi/Bmal1tm1.1Shbi Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+ involves: C57BL/6 * C57BL/6J * DBA	normal behavior/neurological phenotype	J:177865
	normal liver/biliary system phenotype	J:177865
Bmal1tm1.1Shbi/Bmal1tm1.1Shbi Tg(Ckmm-cre)5Khn/0 involves: C57BL/6J * FVB	normal behavior/neurological phenotype	J:177865
	normal muscle phenotype	J:177865
Bmal1tm1.1Weit/Bmal1tm1.1Weit involves: 129S4/SvJae * BALB/cJ	abnormal circadian behavior	J:124157
Bmal1tm1.2Shbi/Bmal1tm1.2Shbi involves: C57BL/6J	abnormal gluconeogenesis	J:177865
	abnormal glucose homeostasis	J:177865
	abnormal lipid level	J:177865
	abnormal locomotor circadian rhythm	J:177865
	normal behavior/neurological phenotype	J:177865
	decreased body weight	J:177865
	decreased circulating HDL cholesterol level	J:177865
	decreased circulating insulin level	J:177865
	decreased circulating VLDL triglyceride level	J:177865
	decreased insulin secretion	J:177865
	decreased susceptibility to diet-induced obesity	J:177865
	decreased total body fat amount	J:177865
	decreased white fat cell size	J:177865
	enlarged pancreatic islets	J:177865
	normal homeostasis/metabolism phenotype	J:177865
	hyperglycemia	J:177865
	impaired glucose tolerance	J:177865
	increased circulating cholesterol level	J:177865
	increased circulating free fatty acids level	J:177865
	increased circulating HDL cholesterol level	J:177865
	increased circulating LDL cholesterol level	J:177865
	increased circulating triglyceride level	J:177865
	increased circulating VLDL cholesterol level	J:177865
	increased liver triglyceride level	J:177865
	increased respiratory quotient	J:177865
	increased sebum secretion	J:177865
	increased skeletal muscle triglyceride level	J:177865
	increased susceptibility to diet-induced hepatic steatosis	J:177865
Bmal1tm1Bra/Bmal1+ involves: 129 * C57BL/6	delayed circadian behavior phase	J:177916
Bmal1tm1Bra/Bmal1tm1Bra B6.129-Bmal1tm1Bra	abnormal circadian behavior	J:125921
	abnormal circadian regulation of heart rate	J:125921
	abnormal circadian regulation of systemic arterial blood pressure	J:125921
	abnormal circulating adrenaline level	J:125921
	abnormal circulating protein level	J:191844
	abnormal cornea morphology	J:110697
	abnormal corneal stroma morphology	J:110697
	abnormal costal cartilage morphology	J:97108
	abnormal gait	J:97108
	abnormal knee joint morphology	J:97108
	abnormal lens fiber morphology	J:110697
	abnormal lens morphology	J:110697
	abnormal ligament morphology	J:97108
	abnormal metabolism	J:110697
	abnormal nitric oxide homeostasis	J:191844
	abnormal posture	J:97108
	abnormal rib morphology	J:97108
	abnormal tail movements	J:97108
	abnormal thoracic cage morphology	J:97108
	abnormal vascular smooth muscle physiology	J:191844
	abnormal venous thrombosis	J:191844
	abnormal vertebral column morphology	J:97108
	calcified calcaneal tendon	J:97108, J:116189
	calcified intervertebral disk	J:97108
	calcified joint	J:97108
	calcified tendon	J:97108
	cataract	J:110697
	corneal epithelium hyperplasia	J:110697
	corneal vascularization	J:110697
	decreased abdominal adipose tissue amount	J:110697
	decreased basophil cell number	J:191844
	decreased body size	J:110697
	decreased body weight	J:97108, J:116189
	decreased circulating adrenaline level	J:125921
	decreased circulating noradrenaline level	J:125921
	decreased heart rate	J:125921
	decreased heart weight	J:110697
	decreased kidney weight	J:110697
	decreased leukocyte cell number	J:110697
	decreased lung weight	J:110697
	decreased lymphocyte cell number	J:110697
	decreased mean systemic arterial blood pressure	J:125921
	decreased muscle weight	J:110697
	decreased prothrombin time	J:191844
	decreased spleen weight	J:110697
	decreased subcutaneous adipose tissue amount	J:110697
	decreased testis weight	J:110697
	decreased total body fat amount	J:110697
	decreased vasodilation	J:191844
	dehydration	J:97108
	ectopic bone	J:97108
	fused joints	J:97108
	normal hematopoietic system phenotype	J:110697
	hypercoagulability	J:191844
	hypotension	J:125921
	impaired leukocyte tethering or rolling	J:191844
	impaired righting response	J:97108
	increased circulating factor VIII level	J:191844
	increased circulating fibrinogen level	J:191844
	increased circulating osteocalcin level	J:97108
	increased eosinophil cell number	J:191844
	increased incidence of corneal inflammation	J:110697
	increased leukocyte cell number	J:191844
	increased lymphocyte cell number	J:191844
increased megakaryocyte cell number	J:191844
increased monocyte cell number	J:110697
increased neutrophil cell number	J:110697, J:191844
increased partial thromboplastin time	J:191844
increased susceptibility to induced thrombosis	J:191844
increased vasoconstriction	J:191844
infertility	J:110697
osteoporosis	J:110697
postnatal growth retardation	J:110697
premature aging	J:110697, J:191844
premature death	J:110697, J:116189
priapism	J:191844
retarded hair growth	J:110697
sacral vertebral fusion	J:97108
normal skeleton phenotype	J:97108
small seminal vesicle	J:110697
thoracic vertebral fusion	J:97108
thrombocytosis	J:191844
vascular smooth muscle hyperplasia	J:191844
weight loss	J:97108, J:110697
Bmal1tm1Bra/Bmal1tm1Bra involves: 129	abnormal circadian behavior phase	J:66502
	abnormal circulating protein level	J:155089
	abnormal eye electrophysiology	J:124157
	abnormal glucose homeostasis	J:131694
	abnormal lipid homeostasis	J:131694
	abnormal locomotor activation	J:66502
	abnormal response to injury	J:155089
	arrhythmic circadian behavior persistence	J:66502
	decreased circulating progesterone level	J:151819
	decreased uterus weight	J:115188
	failure of embryo implantation	J:151819
	female infertility	J:151819
	normal homeostasis/metabolism phenotype	J:151819
	impaired gluconeogenesis	J:131694
	impaired wound healing	J:193286
	increased bone resorption	J:115188
	increased insulin sensitivity	J:131694
	increased osteoblast cell number	J:115188
	increased total fat pad weight	J:115188
	prolonged estrous cycle	J:151819
	normal skeleton phenotype	J:115188
	normal vision/eye phenotype	J:124157
Bmal1tm1Bra/Bmal1tm1Bra involves: 129/Sv * C57BL/6	abnormal B cell differentiation	J:118522
	abnormal circadian sleep/wake cycle	J:135933
	abnormal sleep pattern	J:135933
	abnormal T cell subpopulation ratio	J:118522
	decreased B cell number	J:118522, J:135933
	decreased circulating glucose level	J:135933
	decreased follicular B cell number	J:118522
	decreased IgG1 level	J:118522
	decreased insulin secretion	J:162641
	decreased lymphocyte cell number	J:118522, J:135933
	decreased pancreatic islet number	J:162641
	decreased plasma anion gap	J:135933
	decreased transitional stage B cell number	J:118522
	fragmentation of sleep/wake states	J:135933
	increased blood urea nitrogen level	J:135933
	increased circulating alanine transaminase level	J:135933
	increased circulating aspartate transaminase level	J:135933
	increased neutrophil cell number	J:135933
	premature death	J:135933
	thrombocytosis	J:135933
Bmal1tm1Bra/Bmal1tm1Bra involves: 129/Sv * C57BL/6 * C57BL/6J	abnormal hair cycle	J:151782
	abnormal hair cycle anagen phase	J:151782
	abnormal hair follicle matrix region morphology	J:151782
Bmal1tm1Bra/Bmal1tm1Bra Tg(ACTA1-Arntl)1Jt/0 involves: 129/Sv * C57BL/6J * CD-1	abnormal circadian behavior	J:116189
	calcified calcaneal tendon	J:116189
	decreased body size	J:116189
	normal mortality/aging	J:116189
Bmal1tm1Bra/Bmal1tm1Bra Tg(Scg2-tTA)1Jt/0 Tg(tetO-Arntl)1Jt/0 involves: 129/Sv * C57BL/6J * CD-1	abnormal locomotor activation	J:116189
	normal behavior/neurological phenotype	J:116189
	shortened circadian behavior period	J:116189
Bmal1tm1Bra/Bmal1tm1Weit Syt10tm1.1(icre)Geno/Syt10+ involves: 129S2/SvPas * 129S4/SvJaeSor * C57BL/6	abnormal circadian behavior	J:175596
	shortened circadian behavior period	J:175596
Bmal1tm1Bra/Bmal1tm1Weit Syt10tm1.1(icre)Geno/Syt10tm1.1(icre)Geno involves: 129S2/SvPas * 129S4/SvJaeSor * C57BL/6	abnormal circadian behavior	J:175596
Bmal1tm1Weit/Bmal1tm1Weit Syt10tm1.1(icre)Geno/Syt10+ involves: 129S2/SvPas * 129S4/SvJaeSor * C57BL/6	shortened circadian behavior period	J:175596
Bmal1tm1Weit/Bmal1tm1Weit Tg(Chx10-EGFP/cre,-ALPP)2Clc/0 involves: 129S4/SvJae * C57BL/6	abnormal eye electrophysiology	J:124157
Bmal1tm2Bra/Bmal1tm2Bra Tg(Pdx1-cre)89.1Dam/0 involves: 129 * C57BL/6 * C57BL/6J * CBA * ICR	abnormal pancreatic beta cell physiology	J:162641
	normal behavior/neurological phenotype	J:162641
	decreased insulin secretion	J:162641
	hyperglycemia	J:162641
	impaired glucose tolerance	J:162641
Bmal1tm2Bra/Bmal1tm2Bra Tg(Tek-cre)12Flv/0 involves: C3H * C57BL/6 * C57BL/6J	abnormal protein level	J:155089
	abnormal response to injury	J:155089
	decreased locomotor activity	J:155089
	decreased mean systemic arterial blood pressure	J:155089
	increased heart rate	J:155089